Compare PRT & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | ELUT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 50.8M |
| IPO Year | N/A | 2020 |
| Metric | PRT | ELUT |
|---|---|---|
| Price | $3.45 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 41.5K | ★ 172.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.47% | N/A |
| EPS Growth | N/A | ★ 10.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,375,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.61 | $0.50 |
| 52 Week High | $4.42 | $3.46 |
| Indicator | PRT | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 53.01 |
| Support Level | $3.28 | $0.86 |
| Resistance Level | $4.09 | $1.15 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 60.00 | 13.24 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.